Rare Disease Trial, Recruiting NCT07063719 Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, Recruiting

NCT07063719
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Patient group (people with a rare eye disease):

  • Adults aged 18 or older, including those who are planning to become pregnant
  • People who are willing and able to read and understand the consent forms
  • People who have been diagnosed with one of the following rare eye diseases (a specific diagnosis for each condition is required, sometimes including genetic testing): Aniridia-Associated Keratopathy (AAK), Neurotrophic Keratopathy (NK), Limbal Stem Cell Deficiency (LSCD), Ocular Cicatricial Pemphigoid (OCP), Ocular Chronic Graft-Versus-Host Disease (OC GVHD), Ectrodactyly-Ectodermal dysplasia-Clefting syndrome (EEC), or Corneal Neovascularization (CNV)
  • People who are enrolled in, or covered by, a social security or health insurance scheme

Control group (people without a rare eye disease):

  • Adults aged 18 or older, including those who are planning to become pregnant
  • People who are willing and able to read and understand the consent forms
  • People who have not been diagnosed with any of the rare eye diseases listed above
  • People who are enrolled in, or covered by, a social security or health insurance scheme

Who may not be able to join:

Patient group:

  • People who are currently pregnant or breastfeeding, if the biological sample collection would cause them stress or discomfort
  • People whose cornea is at immediate risk of perforation (a serious structural eye emergency)
  • People who have had eye surgery within the last 3 months
  • People who have had a change in their eye drop medications (type or how often they use them) within the last month
  • People who are under a legal protection or guardianship arrangement

Control group:

  • People who are currently pregnant or breastfeeding
  • People who currently have an active eye infection
  • People whose cornea is at immediate risk of perforation (a serious structural eye emergency)
  • People who have had eye surgery within the last 3 months
  • People who have had a change in their eye drop medications (type or how often they use them) within the last month
  • People who are under a legal protection or guardianship arrangement

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 01 44 27 81 64

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

The expression levels of the genes and proteins

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov